BHV 1600
Alternative Names: BHV-1600Latest Information Update: 17 Aug 2024
At a glance
- Originator Biohaven Pharmaceuticals
- Class Heart failure therapies; Small molecules
- Mechanism of Action Beta 1 adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Dilated cardiomyopathy
Most Recent Events
- 08 Aug 2024 Biohaven Therapeutics plans INTERACT meeting with US FDA for BHV-1600 for Dilated cardiomyopathy in 2H 2024
- 29 Feb 2024 Biohaven Pharmaceuticals expects to file an IND application for Dilated cardiomyopathy in 2H 2024
- 29 Feb 2024 Pharmacodynamics data from a preclinical trial in Dilated cardiomyopathy released by Biohaven Pharmaceuticals